Dendreon (DNDN): Q2 EPS of $0.61 misses by $0.02. Revenue of $80M misses by $6M. Company...

Dendreon (DNDN): Q2 EPS of $0.61 misses by $0.02. Revenue of $80M misses by $6M. Company announces strategic restructuring. Shares currently halted AH. (PR)
From other sites
Comments (3)
  • What_the_facts_say
    , contributor
    Comments (18) | Send Message
    Why has nobody joined the dots between a widely-syndicated article in Reuters which said that this drug might well be killing patients, published on March 30th, and the terrible sales this quarter?

    30 Jul 2012, 05:12 PM Reply Like
  • Lawrence Marc-Aurele
    , contributor
    Comments (106) | Send Message
    We know for certain that the other treatments, chemo, radiation etc. have also killed people. The safety of Provenge was proven well before its approval. Keep in mind that currently, only the sickest, most advanced PCa patients have been allowed in Provenge clinical trials. It is highly unlikely that a healthy patient could be harmed by Provenge.


    The true test of Provenge's worth can only be ascertained by giving it as a first-line treatment without requiring participants to have hormone-refractory PCa.
    30 Jul 2012, 07:22 PM Reply Like
  • julian_desmond
    , contributor
    Comments (6) | Send Message
    This is a pretty misinformed interpretation of this article. The Reuters article suggests that patients receiving the CONTROL vaccine in the study MAY have died earlier that expected. Nothing about Provenge and early deaths.
    30 Jul 2012, 08:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs